Christopher Cano - 22 Sep 2021 Form 4 Insider Report for TFF Pharmaceuticals, Inc.

Reporting relationship: Chief Operating Officer
Issuer ticker: N/A
Reported as of: 22 Sep 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Sep 2021, 16:15:29 UTC
Source filing: View source filing
Reporting owner signature: /s/ Christopher Cano, by Kirk Allen Coleman, as Attorney-in-Fact

Key filing fact

Christopher Cano filed Form 4 for TFF Pharmaceuticals, Inc. on 24 Sep 2021.

Key facts

This page summarizes Christopher Cano's Form 4 filing for TFF Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Sep 2021, 16:15.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TFFP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +43,000
Change %: +27%
Price: $0.000000
Shares after: 200,000
Date: 22 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43,000
Exercise price: $7.93
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Options are granted under TFF Pharmaceuticals, Inc. 2021 Stock Incentive Plan ("Plan") and the exercise of the Options is subject to stockholder approval of the Plan. Subject to stockholder approval of the Plan, each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on September 22, 2022 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on December 22, 2022.